The PIs of tomorrow session at the next LS2 Annual Meeting 2024 will be heldin Lausanne, 14-15. February 2024.
This session offers to postdocs interested in an academic career an opportunity to present a plenary talk similar in format to a professorship interview seminar. A knowledgeable jury panel of professors will evaluate the presentations.
The best presentation will be awarded a prize. However, everyone is a winner, as all presenters in the session will receive feedback from the jury in a one-on-one private session afterwards. Moreover, as a participant in the LS2 Annual Meeting 2024, you will have the opportunity to expand or refresh your network in Switzerland via interaction with scientists in and outside your field.
Only applicants having ties to Switzerland will be considered (i.e. Swiss citizenship, Swiss residency, past or on-going affiliation with a Swiss institution of at least two years by the 2024 meeting). Independent position holders are not eligible.
Find the full list of eligibility and selection criteria and details to apply in the document hereunder.
Questions to the session should be addressed to postdocsession@gmail.com. We are looking forward to your application and hope to welcome you in February 2024 at the LS2 meeting!
Martyna Wroblewska is a Manager of Innovation & Sourcing at BaseLaunch accelerator. BaseLaunch works with scientists and entrepreneurs and helps them build exceptional biotech ventures from scratch, by providing convertible loan financing, access to partners (Roche, J&J, CSL Behring, CMS, Roivant Sciences, BridgeBio, and Pureos Bioventures), and drug development expertise. She studied at the University of Zurich, and before joining BaseLaunch in 2021 worked for a Zurich-based biotech start-up as a Project Leader, where she was responsible for the design, development, and management of projects focused on oncology and vaccine development.
Simon Bredl is in the process of translating his cell based immunotherapy into the startup Trojan Therapeutics. Simon has a background in immunology, virology and molecular biology, with an interest in synthetic biology. After his Postdoc, he worked as a scientist for Redbiotec AG in Schlieren and was part of their success story. At the moment, Simon is working on monocyte-based immunotherapy, comparable to CAR T-cell therapy, for immunological cold, solid tumors.
Gabriel Leventhal is the Chief Scientific Officer of PharmaBiome, an ETH spin-off that is developing multi-strain bacterial consortia to treat diseases linked to the gut microbiome. Gabriel is originally a physicist and a mathematical biologist by training, but has been working in microbial ecology for the last 10 years. Following a postdoc at MIT, he returned to Switzerland to join PharmaBiome and push their mission of developing targeted microbiome live biotherapeutic consortium products.
Joshua Jordi has led EraCal as CEO since its inception. He is a biochemist from ETH by training and completed his PhD in physiology at UZH. Joshua invented EraCal’s foundational platform technology as a postdoctoral fellow at Harvard University. EraCal was founded as a UZH and Harvard University spin-off in 2018 and aims to fight excess weight and obesity as the most widespread health risk globally by developing a novel drug candidate to reduce appetite.
Christian Jost is the co-founder of Athebio and studied DARPins and their biotechnological potential for nearly 10 years in an academic setting. He then extended his knowledge towards pharmaceutical drug development and became a Senior Scientist at Roche-Glycart. With his expertise from both academia and industry, Christian connects the biological ideas and needs of their Pharma partners with the possibilities of Athebio’s Athebody® DARPIn technology.
Registration is now open for 2 upcoming Skills for Scientists events via this link
The bench smart to business smart workshop on September 8th (Dorigny campus) is in collaboration with the HUB-UNIL and will feature a roundtable with alumni working in industry; tips for landing a job from a hiring manager at Merck; information on innovation and patents by the PACTT and insights from an alumni entrepreneur.
The CV checks/job orientation are individual consulations on August 25th of 45 minutes on the Bugnon campus. The schedule of the consulations will be sent upon confrimation of participation. You can alternatively book an individual consulation at any time by writing to this email address.
PIs of tomorrow is the Future of Swiss Research‘ session at the next LS2 Annual Meeting 2024 which will be heldin Lausanne, 14-15. February 2024.
This session offers to postdocs interested in an academic career an opportunity to present a plenary talk similar in format to a professorship interview seminar. A knowledgeable jury panel of professors will evaluate the presentations.
The best presentation will be awarded a prize. However, everyone is a winner, as all presenters in the session will receive feedback from the jury in a one-on-one private session afterwards. Moreover, as a participant in the LS2 Annual Meeting 2024, you will have the opportunity to expand or refresh your network in Switzerland via interaction with scientists in and outside your field.
Only applicants having ties to Switzerland will be considered (i.e. Swiss citizenship, Swiss residency, past or on-going affiliation with a Swiss institution of at least two years by the 2024meeting). Independent position holders are not eligible.
Are you a postgraduate in genetics looking to broaden your horizons? Biopôle has just launched an innovative initiative tailor-made for you!
Introducing the ‘Postgraduate Consulting Group,’ a fantastic opportunity for emerging scientists like you to apply your scientific expertise in an industrial setting. This groundbreaking initiative is designed to bridge the gap between academia and industry, allowing you to contribute to the success of cutting-edge startups in the healthcare sector.
What’s the deal? As a member of the Postgraduate Consulting Group, you’ll get to critically assess and challenge the scientific foundations of technologies developed by select Biopôle healthcare startups. This third-party evaluation not only enhances your skillset but also provides valuable insights to startups seeking investment opportunities.
Partnering with Alcimed, a premier consulting firm specializing in tech-driven industries, Biopôle is paving the way for a unique experience.
Two consulting projects are now open:
Therapeutics – Exploring Allosteric Modulators
Diagnostics – Unraveling the World of Oncology
Don’t miss out on this extraordinary chance to contribute to groundbreaking research while gaining invaluable industry exposure. Apply by August 21, 2023, by sending your CV and motivation letter to info@biopole.ch.
We are delighted to announce that Shanaz Diessler emerged victorious at the “EPFL Startup Champions Seed Night 2023,” securing the esteemed Musy Prize for her groundbreaking high-tech start-up project. The Musy Prize, awarded biennially, recognizes exceptional women entrepreneurs in the field of high technology, and Dr Diessler’s achievement is a testament to her ingenuity and entrepreneurial prowess. Congratulations to Shanaz on this well-deserved recognition of her visionary work!
